Abstract
Fibrosis, the pathological end stage of chronic inflammatory diseases, results from extracellular matrix deposition by fibrogenic fibroblasts. In this issue of Cell Stem Cell, Sobecki et al. (2022) develop a novel vaccination-based immunotherapy against fibrogenic progenitor-restricted antigens, leading to the regression of fibrosis in concert with liver and lung regeneration.